Lehrach, Hans
Curtis, Jon
Lange, Bodo
Ogilvie, Lesley A.
Gauss, Richard
Steininger, Christoph
Scholz, Erhard
Kreck, Matthias
Funding for this research was provided by:
Alacris Theranostics
City Government, Vienna
Medizinische Universität Wien
Max Planck Institute for Molecular Genetics
Article History
Received: 19 June 2021
Accepted: 14 March 2022
First Online: 4 April 2022
Competing interests
: HL is co-founder and Chairman of the Company Board, and BL, JC and LO are employees of or consultants for Alacris Theranostics GmbH, a personalized medicine company which has developed a high throughput RT-PCR testing platform for SARS-CoV-2. CS is founder of LEAD Horizon, a COVID-19 testing company in Vienna. All other authors declare no competing interests.